Lannett Company has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International plc for an upfront payment plus future milestone payments.   The portfolio primarily consists of oral solutions with a few semi-solid products.  For the 12 months ending in March 2018, combined sales of the acquired products were in excess of $175 million, according to IMS.   “This transaction perfectly dovetails with our strategy to grow our top and bottom...